The intervention being tested is BNT327, administered in two dose levels, combined with standard chemotherapy drugs such as etoposide, carboplatin, paclitaxel, and topotecan. The purpose is to ...

Doctors are looking for ways to improve treatment for NSCLC. In this trial, they are looking at an experimental drug called BNT327. It is a new type of immunotherapy drug . It works in 2 ways. It aims ...

The update on this clinical study could influence BioNTech’s stock performance by potentially boosting investor confidence if the results are favorable. The involvement of collaborators like ...

This trial is comparing BNT327 and standard chemotherapy with atezolizumab and standard chemotherapy. It is for people having their first treatment for small cell lung cancer that has spread within ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

BNT327/PM8002 is designed to restore effector T-cell function by binding to PD-L1, as well as localize VEGF-A neutralization within the tumor microenvironment, therefore reversing the dampening of ...

BioNTech SE has signed a definitive agreement to acquire Biotheus, a clinical-stage biotech company, with the goal of enhancing its oncology strategy. The acquisition includes access to BNT327/PM8002, ...

Today, we announced a global strategic partnership with BioNTech SE to co-develop and co-commercialize BNT327, an investigational, next-generation PD-L1/VEGF bispecific antibody being studied ...

German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said ...